ReviewDiscover oncology2026
Cytochrome c as a central regulator of mitochondrial function in cancer metabolism.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis, characterization, and anticancer potency of sulfadiazine salicylaldehyde-based Schiff bases.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cytochrome c (Cytc) becomes a crucial regulator, determining the fate of cells at the confluence of apoptosis and metabolism. From its primary origin as an electron transporter in the mitochondrial electron transport chain (ETC), Cytc has ascended to a crucial role in apoptosis, triggering cascades of cellular deathupon liberation from the mitochondria.The intricate interplay between Cytc and apoptosis protease-activating factor-1 (Apaf-1) culminates in the apoptosome formation and activation of the cascade of caspase, underscoring the significance of Cytc in regulating cell death pathways. Moreover, tale of Cytc is adorned with post-translational modifications, particularly phosphorylation, which fine-tune its functions in respiration and apoptosis, adding layers of complexity to its regulatory effectiveness. Cytc becomes a lighthouse in the intricate web of cancer, its expression patterns providing hints about prognosis and paths toward treatment. Nevertheless, the story becomes more complex as Cytc becomes entangled in the metabolic reprogramming of cancer cells, implying a crucial involvement in tumor progression and treatment resistance. Collectively, these findings highlight Cytc as a multifunctional regulator of cellular fate that integrates mitochondrial respiration, apoptotic signalling, and metabolic reprogramming, suggesting new opportunities for cancer diagnosis and therapeutic intervention. Even if progress has been made, the story of Cytc is far from over, demanding more investigation into its complexities and biological consequences related to cancer. It represents a therapeutic target in the fight against cancer considering its substantial role in tumor metabolism. It promises a future in which creative solutions to the challenges of cellular destiny will be found. In this review, we have tried to highlight the multidimensional realm of Cytc, connecting threads between apoptosis, metabolic reprogramming, and the Warburg effect in line with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.